> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Adakveo Regulatory Review Period Determined
- URL: https://www.fdaweb.com/adakveo-regulatory-review-period-determined/
- Published: 2021-11-03T12:00:00.000Z
- Updated: 2026-09-14T17:21:20.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5150510

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Novartis’ Adakveo (crizanlizumab-tmca), indicated to reduce the frequency of vaso-occlusive crises in adults and pediatric patients with sickle cell disease. The review period is 3,152 days, which includes 2,968 days that occurred during the testing phase and 184 days during the approval phase. To view the notice, click [here](https://public-inspection.federalregister.gov/2021-24070.pdf?ref=fdaweb.com).